Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLO NASDAQ:AVIR NASDAQ:IMMX NASDAQ:JBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$1.13-3.4%$1.19$0.86▼$3.78$259.60M0.363.10 million shs1.59 million shsAVIRAtea Pharmaceuticals$3.14-4.8%$3.52$2.45▼$4.14$249.18M0.24261,358 shs182,103 shsIMMXImmix Biopharma$2.10-5.4%$2.47$1.26▼$3.20$64.01M0.25173,362 shs184,883 shsJBIOJade Biosciences$7.70-0.8%$8.09$6.57▼$105.00$253.18M1.0484,226 shs37,906 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics0.00%-1.74%+5.61%-15.67%-61.17%AVIRAtea Pharmaceuticals0.00%-6.82%-10.03%-0.63%-14.44%IMMXImmix Biopharma0.00%-2.33%-4.11%-10.64%+12.90%JBIOJade Biosciences0.00%-0.90%+13.74%+13.91%+769,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$1.13-3.4%$1.19$0.86▼$3.78$259.60M0.363.10 million shs1.59 million shsAVIRAtea Pharmaceuticals$3.14-4.8%$3.52$2.45▼$4.14$249.18M0.24261,358 shs182,103 shsIMMXImmix Biopharma$2.10-5.4%$2.47$1.26▼$3.20$64.01M0.25173,362 shs184,883 shsJBIOJade Biosciences$7.70-0.8%$8.09$6.57▼$105.00$253.18M1.0484,226 shs37,906 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics0.00%-1.74%+5.61%-15.67%-61.17%AVIRAtea Pharmaceuticals0.00%-6.82%-10.03%-0.63%-14.44%IMMXImmix Biopharma0.00%-2.33%-4.11%-10.64%+12.90%JBIOJade Biosciences0.00%-0.90%+13.74%+13.91%+769,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLOAllogene Therapeutics 2.75Moderate Buy$8.44647.30% UpsideAVIRAtea Pharmaceuticals 2.50Moderate Buy$6.0091.08% UpsideIMMXImmix Biopharma 2.50Moderate Buy$8.00280.95% UpsideJBIOJade Biosciences 3.00Buy$16.00107.79% UpsideCurrent Analyst Ratings BreakdownLatest IMMX, JBIO, ALLO, and AVIR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025IMMXImmix BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$7.00 ➝ $8.008/25/2025IMMXImmix BiopharmaZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/14/2025JBIOJade BiosciencesWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$17.00 ➝ $18.008/4/2025ALLOAllogene TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Perform8/4/2025ALLOAllogene TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral7/14/2025JBIOJade BiosciencesJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$16.006/16/2025JBIOJade BiosciencesGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$14.00(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLOAllogene TherapeuticsN/AN/AN/AN/A$2.01 per shareN/AAVIRAtea PharmaceuticalsN/AN/AN/AN/A$5.20 per shareN/AIMMXImmix BiopharmaN/AN/AN/AN/A$0.48 per shareN/AJBIOJade BiosciencesN/AN/AN/AN/A$92.88 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLOAllogene Therapeutics-$257.59M-$1.11N/AN/AN/AN/A-55.99%-42.75%11/6/2025 (Estimated)AVIRAtea Pharmaceuticals-$168.38M-$1.61N/AN/AN/AN/A-32.55%-30.47%11/6/2025 (Estimated)IMMXImmix Biopharma-$21.61M-$0.77N/AN/AN/AN/A-205.35%-110.63%11/11/2025 (Estimated)JBIOJade Biosciences-$69.63M-$30.33N/A∞N/AN/A-51.96%-47.65%N/ALatest IMMX, JBIO, ALLO, and AVIR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025ALLOAllogene Therapeutics-$0.28-$0.23+$0.05-$0.23N/AN/A8/13/2025Q2 2025JBIOJade Biosciences-$0.43-$0.86-$0.43-$0.86N/AN/A8/8/2025Q1 2025IMMXImmix Biopharma-$0.21-$0.22-$0.01-$0.22N/AN/A8/7/2025Q2 2025AVIRAtea Pharmaceuticals-$0.46-$0.44+$0.02-$0.44N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLOAllogene TherapeuticsN/AN/AN/AN/AN/AAVIRAtea PharmaceuticalsN/AN/AN/AN/AN/AIMMXImmix BiopharmaN/AN/AN/AN/AN/AJBIOJade BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLOAllogene TherapeuticsN/A8.928.92AVIRAtea PharmaceuticalsN/A19.1719.17IMMXImmix BiopharmaN/A1.231.23JBIOJade BiosciencesN/A10.3110.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLOAllogene Therapeutics83.63%AVIRAtea Pharmaceuticals86.67%IMMXImmix Biopharma11.26%JBIOJade BiosciencesN/AInsider OwnershipCompanyInsider OwnershipALLOAllogene Therapeutics13.20%AVIRAtea Pharmaceuticals18.10%IMMXImmix Biopharma55.40%JBIOJade Biosciences24.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLOAllogene Therapeutics310221.88 million192.59 millionOptionableAVIRAtea Pharmaceuticals7079.36 million64.99 millionOptionableIMMXImmix Biopharma928.83 million12.86 millionOptionableJBIOJade Biosciences2032.63 million24.50 millionN/AIMMX, JBIO, ALLO, and AVIR HeadlinesRecent News About These CompaniesJade Biosciences (NASDAQ:JBIO) Stock Price Up 1.9% - Still a Buy?September 12 at 5:18 AM | marketbeat.comJade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of ...September 2, 2025 | bakersfield.comBJade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being ...September 2, 2025 | finance.yahoo.comJade Biosciences Initiates Phase 1 Trial for JADE101 as Potential Disease-Modifying Treatment for IgANSeptember 2, 2025 | quiverquant.comQJade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA NephropathySeptember 2, 2025 | globenewswire.comJade Biosciences Reports Q2 2025 Financial ResultsAugust 26, 2025 | tipranks.comJade Biosciences, Inc. to Participate in Key Biotechnology Conferences in September 2025August 25, 2025 | quiverquant.comQJade Biosciences to Participate in Upcoming ConferencesAugust 25, 2025 | globenewswire.comJade Biosciences Posts Wider Loss in Q2August 14, 2025 | theglobeandmail.comJade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 13, 2025 | globenewswire.comJade Biosciences, Inc. Common Stock (JBIO) Analyst ResearchJuly 31, 2025 | nasdaq.comInstitutional investors in Jade Biosciences, Inc. (NASDAQ:JBIO) must be dismayed after prices dropped by 16% last weekJuly 30, 2025 | finance.yahoo.comJBIO - Jade Biosciences Inc Financials | MorningstarJuly 11, 2025 | morningstar.comMJade Biosciences, Inc. to Participate in H.C. Wainwright and Stifel Biotech Investor ConferencesJuly 8, 2025 | quiverquant.comQJade Biosciences to Participate in Two Upcoming Investor ConferencesJuly 8, 2025 | globenewswire.comJade Biosciences Inc. Stock Grades | JBIO | Barron'sJuly 5, 2025 | barrons.comJade Biosciences Inc. Research & Ratings | JBIO | Barron'sJuly 5, 2025 | barrons.comJade Biosciences appoints Brad Dahms as new CFOJuly 2, 2025 | investing.comJade Biosciences, Inc. Appoints Brad Dahms as Chief Financial Officer to Drive Growth and Innovation - NasdaqJuly 2, 2025 | nasdaq.comJade Biosciences, Inc. Appoints Brad Dahms as Chief Financial Officer to Drive Growth and InnovationJuly 1, 2025 | quiverquant.comQJade Biosciences Appoints Brad Dahms as Chief Financial OfficerJuly 1, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 2025Kratos Keeps Climbing After Q2, But Valuation Risk LoomsBy Leo Miller | August 18, 2025Oracle Has Spoken: AI Changes EverythingBy Thomas Hughes | September 10, 2025IMMX, JBIO, ALLO, and AVIR Company DescriptionsAllogene Therapeutics NASDAQ:ALLO$1.13 -0.04 (-3.42%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.13 0.00 (0.00%) As of 09/12/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.Atea Pharmaceuticals NASDAQ:AVIR$3.14 -0.16 (-4.85%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$3.20 +0.06 (+2.04%) As of 09/12/2025 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.Immix Biopharma NASDAQ:IMMX$2.10 -0.12 (-5.41%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.10 0.00 (0.00%) As of 09/12/2025 05:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.Jade Biosciences NASDAQ:JBIO$7.70 -0.06 (-0.77%) As of 09/12/2025 04:00 PM EasternAerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
